孕期及哺乳期接种Tdap疫苗后婴儿生长与医疗利用评估
该回顾性队列研究基于美国两个医疗系统2014-2022年电子健康记录,纳入单胎活产孕妇及其婴儿,评估孕期或哺乳期接种Tdap疫苗与婴儿生长及医疗利用的关联。孕期接种与生长迟缓、体重增长缓慢及急诊就诊无关联,但与门诊就诊率略有增加相关;哺乳期接种未见关联。
要点
- 孕期接种Tdap不增加婴儿生长迟缓或体重增长缓慢风险。
- 孕期接种Tdap与婴儿急诊就诊无关联,门诊就诊率略有增加。
- 哺乳期接种Tdap与婴儿生长及医疗利用均无关联。
核心结论
- 孕期接种Tdap疫苗未与婴儿不良生长结局或急诊就诊相关联。
- 孕期接种Tdap与每名婴儿门诊就诊率略有增加相关,但不能排除健康寻求行为残余混杂。
- 哺乳期接种Tdap与婴儿生长及医疗利用无关联。
研究设计与样本
- 回顾性队列研究,使用美国两个医疗系统2014-2022年电子健康记录。
- 纳入单胎活产孕妇及其连接婴儿;孕期分析比较≥27孕周接种Tdap与至产后90天未接种者。
- 产后分析限于母乳喂养者,比较产后90天内接种Tdap与未接种者。
- 婴儿生长结局评估于3-12月龄,医疗利用结局统计至产后6个月(排除未保险婴儿)。
主要发现
- 孕期接种Tdap与生长迟缓无关联(aPR: 0.96, 95% CI: 0.85-1.09)。
- 孕期接种Tdap与体重增长缓慢无关联(aPR: 0.93, 95% CI: 0.81-1.07)。
- 孕期接种Tdap与急诊就诊无关联(aRR: 1.00, 95% CI: 0.84-1.18),但与门诊就诊率略有相关(aRR: 1.07, 95% CI: 1.01-1.12)。
- 哺乳期接种Tdap与婴儿生长及医疗利用均无关联。
关键数值与推荐
- 孕期接种定义为≥27孕周接种Tdap,对照为至产后90天无Tdap接种。
- 生长迟缓与体重增长缓慢定义为<5百分位。
- 医疗利用包括门诊就诊(含健康访视)和急诊就诊计数。
临床怎么用
- 孕期接种Tdap疫苗不增加婴儿生长不良或急诊就诊风险,支持现有免疫推荐。
- 孕期接种后婴儿门诊就诊率轻度增加可能反映健康寻求行为差异,需结合临床评估。
- 哺乳期接种Tdap未见婴儿生长或医疗利用异常,可据此解答接种顾虑。
局限性
- 回顾性观察设计不能排除残余混杂,尤其健康寻求行为。
- 医疗利用分析排除未保险婴儿,可能影响外推性。
- 哺乳期分析样本量较小(3034和3191人),统计效能有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There are limited data on infant growth and healthcare utilization following perinatal Tdap vaccination. OBJECTIVE: To assess associations of Tdap vaccination during pregnancy or when given to lactating individuals with infant growth and healthcare utilization. STUDY DESIGN: We conducted a retrospective cohort study using electronic health records from two US healthcare systems. Prenatal care patients with a singleton live birth (2014-2022) and their linked infants were included. For pregnancy analyses, we compared outcomes in infants of those who received Tdap vaccination at ≥27 gestational weeks to those with no Tdap up to 90 days after delivery. For postpartum analyses, restricted to human milk feeders, we compared Tdap vaccination within 90 days after delivery versus none. Infant growth outcomes assessed between 3 and 12 months of age were growth faltering and slow weight gain (<5th percentile). Infant healthcare utilization outcomes were counts of outpatient visits, including well visits, and emergency department (ED) visits up to 6 months after delivery, excluding uninsured infants. We estimated adjusted prevalence ratios (aPR), or rate ratios (aRR), and 95% confidence intervals (CI). RESULTS: There were 33,261 and 25,335 pregnancies eligible for infant growth and healthcare utilization analyses, respectively. Tdap vaccination during pregnancy was not associated with growth faltering (aPR: 0.96, 95% CI: 0.85-1.09), slow weight gain (aPR: 0.93, 95% CI: 0.81-1.07) or ED visits (aRR: 1.00, 95% CI: 0.84-1.18), but was slightly associated with the rate of outpatient visits (aRR: 1.07, 95% CI: 1.01-1.12). No associations were observed among the 3034 and 3191 lactating individuals eligible for infant growth and healthcare utilization analyses, respectively. CONCLUSION: Tdap vaccination during pregnancy was not associated with adverse infant growth outcomes or ED visits. Although Tdap vaccination during pregnancy was associated with a slight increase in outpatient visits per infant, residual confounding by health seeking behavior could not be ruled out.
引用
- Palmsten K, Cao J, Vazquez-Benitez G, et al. Assessment of infant growth and health care utilization following tetanus, diphtheria, pertussis (Tdap) vaccination during pregnancy and lactation. Vaccine. 2026. PMID: 42702141. doi:10.1016/j.vaccine.2026.129123
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。